Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

v3.24.2.u1
NON CONTROLLING INTEREST (Tables)
6 Months Ended
Jun. 30, 2024
NON CONTROLLING INTEREST  
Schedule of net loss attributable to non-controlling interest

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (67,251 )

 

$ (1,072 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (16,275 )

 

$ (375 )

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (1,849 )

 

$ (1,881 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (448 )

 

$ (658 )

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (68,800 )

 

$ (1,964 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (16,650 )

 

$ (687 )

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (3,296 )

 

$ (3,550 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (798 )

 

$ (1,242 )
Schedule of changes in non controlling interest

Balance, December 31, 2023

 

$ (128,834 )

Net loss attributable to the non-controlling interest

 

 

(17,337 )

Balance, June 30, 2024

 

 

(146,171 )

Balance, December 31, 2022

 

$ (125,257 )

Net loss attributable to the non-controlling interest

 

 

(2,040 )

Balance, June 30, 2023

 

 

(127,297 )